It had posted a net profit of Rs 360.93 crore for the April-June quarter of the 2013-14 fiscal, Dr Reddy's said in a filing to the BSE.
Net sales of the company in Q1, 2014-15, rose to Rs 3,517.54 crore, up 23.64 per cent from Rs 2,844.92 crore in the year-ago period.
Dr Reddy's Laboratories said selling, general and administrative expenses rose to Rs 1,067.89 crore in the quarter under review from Rs 879.36 crore in the year-ago period.
The research and development expenses also rose to Rs 387.53 crore for the quarter, from Rs 242.97 crore in Q1, 2013-14.
Shares of Dr Reddy's were trading at Rs 2,824.90 apiece on the afternoon trade, up 2.10 per cent from its previous close on the BSE.
Generic sales revenue from North America stood at Rs 1,648 crore with a year-on-year growth of 51 per cent.
Four new products were launched during the quarter in North America.
Revenues (generic sales) from India were recorded at Rs 400 crore, a rise of 15 per cent over the year-ago quarter.
Emerging market revenues have shown a growth of 19 per cent at Rs 7,120 crore.
Generic Sales from Europe declined by 7 per cent to Rs 146 crore during the first quarter as compared to the same period last fiscal; while that from Russia and other CIS countries recorded 8 per cent growth to Rs 486 crore.
Income from Pharmaceutical Services and Active Ingredients vertical declined by 6 per cent to Rs 550 crore.
During the quarter, the company launched 25 new generic products, filed 27 new product applications and 20 DMFs globally.